Article
Public, Environmental & Occupational Health
Ye Seul Jang, Yu Shin Park, Hyunkyu Kim, Kyungduk Hurh, Eun-Cheol Park, Suk-Yong Jang
Summary: This study aimed to explore the association between sedentary time and chronic kidney disease (CKD) in the South Korean population. The results showed that women who sat for more than 12 hours per day had a significantly higher risk of CKD, regardless of their physical activity levels. Furthermore, among women who sat for over 12 hours, those with low levels of physical activity had a higher risk of CKD.
Article
Clinical Neurology
Mengyi Liu, Yanjun Zhang, Sisi Yang, Qimeng Wu, Ziliang Ye, Chun Zhou, Panpan He, Yuanyuan Zhang, Fan Fan Hou, Xianhui Qin
Summary: This study investigates the bidirectional associations between renal function and depression in a cohort of young and middle-aged adults. The results show that depression is associated with CKD development, and CKD is associated with an increased risk of depression.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Article
Endocrinology & Metabolism
Jialing Zhang, Aihua Zhang
Summary: The relationship between Klotho and cognitive function in chronic kidney disease patients with albuminuria is examined in this study. The findings suggest that increased levels of Klotho are associated with improved cognitive function in CKD patients with microalbuminuria. Further research is needed to investigate if Klotho could serve as a beneficial biomarker for cognitive health and neurodegeneration.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Natalia Chebotareva, Anatoliy Vinogradov, Valerie McDonnell, Natalia V. Zakharova, Maria I. Indeykina, Sergey Moiseev, Evgeny N. Nikolaev, Alexey S. Kononikhin
Summary: CKD is a non-specific kidney disease that causes gradual decline in kidney function, posing significant risks for death and other complications. Protein/peptide biomarkers can be used for early non-invasive diagnosis and may provide new approaches for targeted therapy. Mass spectrometry approaches offer valuable insights into understanding CKD progression.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Clinical Neurology
Kaori Miwa, Kazunori Toyoda
Summary: Chronic kidney disease (CKD) is associated with an increased risk of stroke and dementia, with common structural brain abnormalities observed in patients with CKD. The brain and kidney exhibit similar impairments and susceptibility to vascular injury, suggesting a significant impact of kidney function on brain aging. However, the exact pathophysiology of structural brain abnormalities in CKD remains unclear.
FRONTIERS IN NEUROLOGY
(2022)
Review
Biochemistry & Molecular Biology
Wiktoria Baran, Julia Krzeminska, Magdalena Szlagor, Magdalena Wronka, Ewelina Mlynarska, Beata Franczyk, Jacek Rysz
Summary: Mineralocorticoid receptor antagonists have a broad spectrum of potential actions and have shown healing effects in various diseases. However, their use in CKD patients is controversial, with steroidal MRA often leading to hyperkalemia complications. Recent studies suggest that nonsteroidal MRAs have fewer side effects.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Pedro Caetano Pinto, Cindy Roennau, Martin Burchardt, Ingmar Wolff
Summary: Kidney cancer and chronic kidney disease have different clinical management strategies, but share closely related cellular and molecular mechanisms, both involving the kidney's response to hypoxia. Fibrosis is a common factor in deteriorating renal function in both conditions.
Review
Biochemistry & Molecular Biology
Catarina Marreiros, Carla Viegas, Dina Simes
Summary: Chronic kidney disease (CKD) patients are at higher risk of developing early cardiovascular disease (CVD), with vascular calcification (VC) being a strong predictor of CVD risk. Diagnosis of VC in CKD population is challenging due to its complexity, but imaging biomarkers and circulating biomarkers play important roles in detection and monitoring, providing valuable insights for management of CVD risk.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Urology & Nephrology
Huda Al-Wahsh, Ngan N. Lam, Robert R. Quinn, Paul E. Ronksley, Manish M. Sood, Brenda Hemmelgarn, Navdeep Tangri, Thomas Ferguson, Marcello Tonelli, Pietro Ravani, Ping Liu
Summary: This study compared the performance of calculated ACR and measured ACR in predicting kidney failure and death without kidney failure in patients with chronic kidney disease. The results suggest that calculated ACR, particularly PCR-calculated ACR, may have better predictive performance than dipstick-calculated ACR.
KIDNEY INTERNATIONAL
(2022)
Article
Nutrition & Dietetics
Lei Yin, Xiaokang Dong, Wei Liao, Xiaotian Liu, Zhaohui Zheng, Dongwei Liu, Chongjian Wang, Zhangsuo Liu
Summary: The study aimed to investigate the relationship between beans consumption and indicators of kidney injury and CKD prevalence in rural adults. It was found that higher beans intake was associated with a lower prevalence of CKD and albuminuria. Each 50g/day increase in beans intake was significantly associated with a 5% decrease in albuminuria and a 4% decrease in CKD prevalence. This suggests that promoting soy food intake may help reduce the occurrence of CKD in rural adults.
FRONTIERS IN NUTRITION
(2023)
Review
Pharmacology & Pharmacy
Zhonghong Yan, Guanran Wang, Xingyang Shi
Summary: Chronic kidney disease (CKD) poses a serious public health concern globally, with issues including inaccurate diagnosis, dependency on biopsies, and multifactorial prognosis challenges in clinical treatment and management. Developing effective biomarkers is crucial for improving CKD prognosis and clinical management.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Transplantation
Danilo Fliser, Christoph Wanner
Summary: Progressive chronic kidney disease in individuals with type 2 diabetes mellitus is a global public health issue with challenges in predicting the individual course of the disease progression. Patterns of progression in CKD patients include both linear and nonlinear trajectories of GFR loss, with kidney function potentially remaining stable for years in the elderly.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2021)
Review
Urology & Nephrology
Shilna Muttickal Swaminathan, Indu Ramachandra Rao, Srinivas Vinayak Shenoy, Attur Ravindra Prabhu, Pooja Basthi Mohan, Dharshan Rangaswamy, Mohan Bhojaraja, Shivashankara Kaniyoor Nagri, Shankar Prasad Nagaraju
Summary: The global burden of diabetic kidney disease (DKD), a predominant cause of end-stage renal disease (ESRD), is increasing. DKD is closely associated with cardiovascular disease and morbidity in all types of diabetes. Predicting progression with albuminuria and eGFR is challenging, especially in non-proteinuric DKD patients. The pathogenesis of DKD involves injury to all components of the nephron, and albuminuria is only an indicator of glomerular injury. Alternative and clinically significant early biomarkers are needed to improve targeted and effective treatment for DKD patients and reduce the burden of DKD and ESRD.
INTERNATIONAL UROLOGY AND NEPHROLOGY
(2023)
Article
Transplantation
Hyoungnae Kim, Young Youl Hyun, Young Su Joo, Hae-Ryong Yun, Yaeni Kim, Ji Yong Jung, Jong Cheol Jeong, Jayoun Kim, Jung Tak Park, Tae-Hyun Yoo, Shin-Wook Kang, Kook-Hwan Oh, Seung Hyeok Han, KNOW CKD Investigat
Summary: The study compares the predictive performances of albuminuria and proteinuria in patients with chronic kidney disease (CKD). The results show that measuring albuminuria is preferred over estimating it with the protein:creatinine ratio in patients with low albuminuria levels. However, estimating albuminuria using the ratio is superior in severe cases of albuminuria and nephrotic-range proteinuria.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2023)
Article
Cardiac & Cardiovascular Systems
Dea Haagensen Kofod, Nicholas Carlson, Ellen Freese Ballegaard, Thomas Peter Almdal, Christian Torp-Pedersen, Gunnar Gislason, Jesper Hastrup Svendsen, Bo Feldt-Rasmussen, Mads Hornum
Summary: This study investigated the risk of cardiovascular mortality in patients with advanced chronic kidney disease (CKD). The results showed that diabetes, albuminuria, and anemia were significant risk factors for cardiovascular mortality, while the predictive value of LDL-cholesterol for cardiovascular mortality in advanced CKD may be limited.
CARDIOVASCULAR DIABETOLOGY
(2023)
Article
Transplantation
Jennifer B. Green, Amy K. Mottl, George Bakris, Hiddo J. L. Heerspink, Johannes F. E. Mann, Janet B. McGill, Masaomi Nangaku, Peter Rossing, Charlie Scott, Alain Gay, Rajiv Agarwal
Summary: This study aims to investigate the efficacy of dual therapy with finerenone and an SGLT2i in reducing chronic kidney disease and type 2 diabetes. The results will provide important insights for improving treatment methods for kidney disease and cardiovascular risks.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2023)
Article
Endocrinology & Metabolism
Peter Rossing, Rajiv Agarwal, Stefan D. Anker, Gerasimos Filippatos, Bertram Pitt, Luis M. Ruilope, Vivian Fonseca, Guillermo E. Umpierrez, Maria Luiza Caramori, Amer Joseph, Marc Lambelet, Robert Lawatscheck, George L. Bakris
Summary: This study investigated the effect of GLP-1RA use on the outcomes of patients with CKD and T2D treated with finerenone. The results showed that the use of GLP-1RA did not affect the cardiorenal benefits of finerenone.
DIABETES OBESITY & METABOLISM
(2023)
Review
Transplantation
Panagiotis Georgianos, Georgios Tziatzios, Stefanos Roumeliotis, Vasilios Vaios, Vasiliki Sgourogoulou, Dimitrios G. Tsalikakis, Vassilios Liakopoulos, Rajiv Agarwal
Summary: This meta-analysis study found that the use of ACEIs/ARBs is not associated with a significantly lower risk of cardiovascular events and all-cause mortality among patients on dialysis when compared with placebo or no add-on treatment.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2023)
Review
Urology & Nephrology
Rajiv Agarwal, James Burton, Maurizio Gallieni, Kamyar Kalantar-Zadeh, Gert Mayer, Carol Pollock, Jacek C. Szepietowski
Summary: Despite the limited increase in life expectancy for patients with end-stage kidney disease after the breakthrough of kidney replacement therapy, the quality of life and relief of symptoms have become increasingly important to patients. Currently, most dialysis-associated symptoms and adverse effects do not have approved treatments, and the few available treatments may add further adverse effects. This article demonstrates how understanding the pathophysiology of a particular symptom (chronic kidney disease-associated pruritus) in dialysis led to the development and regulatory approval of a treatment for that symptom. This approach can be applied to other dialysis-associated symptoms, improving the remaining years of patients' lives.
CLINICAL KIDNEY JOURNAL
(2023)
Article
Urology & Nephrology
Rajiv Agarwal, Bertram Pitt, Biff F. Palmer, Csaba P. Kovesdy, Ellen Burgess, Gerasimos Filippatos, Jolanta Malyszko, Luis M. Ruilope, Patrick Rossignol, Peter Rossing, Roberto Pecoits-Filho, Stefan D. Anker, Amer Joseph, Robert Lawatscheck, Daniel Wilson, Martin Gebel, George L. Bakris
Summary: This study compared the differences in blood pressure reduction and hyperkalemia risk between nonsteroidal MRA finerenone and steroidal MRA spironolactone +/- a potassium binder in patients with treatment-resistant hypertension and chronic kidney disease. The results showed that finerenone had a lower reduction in blood pressure and lower risk of hyperkalemia and treatment discontinuation compared to spironolactone with or without patiromer.
CLINICAL KIDNEY JOURNAL
(2023)
Review
Peripheral Vascular Disease
Panagiotis Georgianos, Rajiv Agarwal
Summary: Steroidal mineralocorticoid-receptor-antagonists (MRAs) have limited use in high-risk patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) due to the associated risk of hyperkalemia and hormonal side effects. Finerenone, a novel nonsteroidal MRA, has shown promising results in reducing cardiovascular and kidney failure outcomes in T2DM patients with a broad spectrum of CKD. Further research is underway to investigate the potential benefits of combining finerenone with a sodium-glucose co-transporter type 2 (SGLT-2) inhibitor.
AMERICAN JOURNAL OF HYPERTENSION
(2023)
Article
Endocrinology & Metabolism
Janet B. B. McGill, Rajiv Agarwal, Stefan D. D. Anker, George L. L. Bakris, Gerasimos Filippatos, Bertram Pitt, Luis M. M. Ruilope, Andreas L. L. Birkenfeld, Maria L. L. Caramori, Meike Brinker, Amer Joseph, Andrea Lage, Robert Lawatscheck, Charlie Scott, Peter Rossing, FIDELIO-DKD Investigator, FIGARO-DKD Investigator
Summary: The aim of this study was to evaluate the effect of finerenone on cardiorenal outcomes and diabetes progression, and to assess its interaction with baseline HbA1c, HbA1c variability, diabetes duration and baseline insulin use. The results showed consistent risk reductions in cardiovascular and kidney outcomes with finerenone compared to placebo across subgroups. Higher HbA1c variability was associated with an increased risk of cardiorenal outcomes. The study concludes that finerenone is effective regardless of baseline characteristics. Overall, the study is rated 9 out of 10.
DIABETES OBESITY & METABOLISM
(2023)
Article
Peripheral Vascular Disease
Rajiv Agarwal, Luis M. Ruilope, Gema Ruiz-Hurtado, Hermann Haller, Roland E. Schmieder, Stefan D. Anker, Gerasimos Filippatos, Bertram Pitt, Peter Rossing, Marc Lambelet, Christina Nowack, Peter Kolkhof, Amer Joseph, George L. Bakris
Summary: Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, was found to reduce 24-hour, daytime, and nighttime systolic blood pressure in patients with chronic kidney disease and type 2 diabetes.
JOURNAL OF HYPERTENSION
(2023)
Editorial Material
Transplantation
Rajiv Agarwal, Denis Fouque
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2023)
Article
Endocrinology & Metabolism
David Z. I. Cherney, Ele Ferrannini, Guillermo E. Umpierrez, Anne L. Peters, Julio Rosenstock, David R. Powell, Michael J. Davies, Phillip Banks, Rajiv Agarwal
Summary: This study assessed the efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease. The results showed that sotagliflozin 400 mg significantly reduced HbA1c at 26 weeks, while the 200 mg dose did not show significant reduction. The urine albumin-creatinine ratio decreased at 26 weeks, but the improvements were not sustained at 52 weeks. Adverse events were similar between treatment groups.
DIABETES OBESITY & METABOLISM
(2023)
Editorial Material
Urology & Nephrology
Rajashree Rana, Matthew D. Breyer
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Robert A. Fletcher, Clare Arnott, Patrick Rockenschaub, Aletta E. Schutte, Lewis Carpenter, Muthiah Vaduganathan, Rajiv Agarwal, George Bakris, Tara I. Chang, Hiddo J. L. Heerspink, Meg J. Jardine, Kenneth W. Mahaffey, Bruce Neal, Carol Pollock, Min Jun, Anthony Rodgers, Vlado Perkovic, Brendon L. Neuen
Summary: Using data from CANVAS and CREDENCE trials, this study found that visit-to-visit blood pressure variability is independently associated with the risks of hospitalization for heart failure and all-cause mortality in patients with type 2 diabetes and high cardiovascular risk or chronic kidney disease. However, the use of canagliflozin has little to no effect on blood pressure variability.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2023)
Article
Transplantation
Panagiotis Georgianos, Rajiv Agarwal
Summary: Hypertension is common and poorly controlled in patients with chronic kidney disease (CKD). Accurate BP measurement is crucial. Dietary sodium restriction and the use of renin-angiotensin system blockers are recommended. Thiazide-like diuretic chlorthalidone is effective in patients with stage 4 CKD and uncontrolled hypertension.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2023)
Article
Urology & Nephrology
Rajiv Agarwal, Sanjeev Anand, Kai-Uwe Eckardt, Wenli Luo, Patrick S. Parfrey, Mark J. Sarnak, Christine M. Solinsky, Dennis L. Vargo, Wolfgang C. Winkelmayer, Glenn M. Chertow
Summary: Anemia is common in chronic kidney disease (CKD) and has negative impacts on quality of life and cardiovascular outcomes. Current standard of care for anemia in CKD requires chronic injections, making it less accessible to certain patients. Safety concerns have also been raised regarding the use of erythropoiesis-stimulating agents. The orally active vadadustat may offer advantages over these agents by activating endogenous erythropoietin production.
AMERICAN JOURNAL OF NEPHROLOGY
(2023)
Meeting Abstract
Oncology
Megan Elizabeth Salwei, Shilo Anders, Laurie Novak, Carrie Reale, Jason Slagle, Joyce Harris, Kim Unertl, Paromita Nath, Sankaran Mahadevan, Rajiv Agarwal, Natalie Elliott, Rachel Lee, Matthew B. Weinger, Daniel France
JOURNAL OF CLINICAL ONCOLOGY
(2022)